AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01043458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-126
Description: Matching Placebo for Arms 1 \& 2
Study NCT00883155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl 100 mg Tablets (Invamed Inc.)
Study NCT00883155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin 100 mg Tablets (Glaxo Wellcome)
Study NCT04136145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab for IV
Description: Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
Study NCT04136145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab for SC
Description: Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
Study NCT01198587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid.
Study NCT01198587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
Study NCT03200002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
Study NCT03200002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count \<1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count \<1000/mm3.
Study NCT02259816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02259816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02259816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study NCT02834455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced CT
Description: 50% of patients with unilateral pleural effusion will have performed a CE-CT
Study NCT02834455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET-CT
Description: 50% of patients with unilateral pleural effusion will have performed a PET-CT
Study NCT02286895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pentavalent rotavirus vaccine (PRV)
Description: Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
Study NCT02286895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: measles vaccine (MV)
Description: A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
Study NCT02286895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles vaccine (MV)
Description: A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
Study NCT02286895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: yellow fever vaccine (YFV)
Description: A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
Study NCT02286895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: yellow fever vaccine (YFV)
Description: A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
Study NCT02286895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: meningitis conjugate vaccine (PsA-TT-5μg)
Description: A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
Study NCT02286895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningitis conjugate vaccine (PsA-TT-5μg)
Description: A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
Study NCT00986882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312A
Study NCT00986882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00986882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT04167943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual cured resin modified tricalcium silicate cement
Description: A resin based, dual cured tricalcium silicate based cement
Study NCT01252680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive+Healive
Description: Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
Study NCT01252680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive+Havrix
Description: Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
Study NCT01252680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix+Havrix
Description: Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
Study NCT01252680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix+Healive
Description: Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
Study NCT02569853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-11
Study NCT02569853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00002766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Study NCT00002766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00002766 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00002766 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03240965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological testing
Description: Neuropsychological testing for neglect, agnosia
Study NCT04245852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength education video
Description: The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
Study NCT04245852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard PT care
Description: standard PT care
Study NCT04245852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard PT care
Description: standard PT care
Study NCT04177667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proxeed
Description: Treatment with dietary supplement for male infertility for Proxeed Arm
Study NCT04177667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo for Placebo Arm
Study NCT04524897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children
Description: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
Study NCT03894332 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical Impedance Tomography (EIT)
Description: After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT_0) and the last (SBT_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB_0) and 30 minutes after extubation (SB_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV).
Study NCT01270516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB, hydroxymethylbutyrate
Description: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
Study NCT01270516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA, eicosapentaenoic acid
Description: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
Study NCT03190122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision of the tumor
Description: Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
Study NCT03190122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical excision of the tumor
Description: Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
Study NCT01270516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control
Study NCT03041077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Instaflex Advanced
Description: Joint function
Study NCT03041077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01191333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive Transcranial Magnetic Stimulation
Study NCT01191333 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Device
Description: Placebo Device that simulates active rTMS treatment
Study NCT03373435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin 9-39
Description: Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
Study NCT02587234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripheral nerve stimulation
Description: Non-invasive stimulation of median, ulnar and radial nerves
Study NCT02587234 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: peripheral nerve stimulation
Description: Non-invasive stimulation of median, ulnar and radial nerves
Study NCT03792191 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lumbar Spinal Ultrasonography
Description: Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
Study NCT03792191 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Sham Ultrasound Procedure
Description: Moving the ultrasound probe on the patient's back with the machine in the freeze position.
Study NCT03792191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Landmark Palpation
Description: Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
Study NCT03792191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia using a 25- or 22-gauge spinal needle
Study NCT03792191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Spinal anesthesia using a 25- or 22-gauge spinal needle
Study NCT03792191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT03792191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT03792191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study NCT03792191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study NCT04394117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin Receptor Blockers
Description: Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
Study NCT04394117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03670888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1101
Description: 100 mg/10 mL solution in a single-use vial
Study NCT03670888 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 100 mg/10 mL solution in a single-use vial
Study NCT03373435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
Study NCT02250417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wave sleep surface
Description: The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
Study NCT03460860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)
Description: The intervention is to be taken once daily, for 12 weeks.
Study NCT03460860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention is to be taken once daily, for 12 weeks.